ADA 2021: After strong showing for Soliqua against premixed insulin, Sanofi exec expects 'a lot of interest' among doctors

Years ago, Sanofi's Soliqua hit the diabetes market with the promise of combining an insulin and a GLP-1 medicine in a convenient once-daily treatment option for Type 2 diabetes. So far, though, sales haven't quite matched that promise.

With new trial data presented at the American Diabetes Association's 81st Scientific Sessions on Monday, Sanofi is looking to give its drug a boost in the competitive diabetes field.